scholarly journals Meal Enjoyment and Tolerance in Women and Men

Nutrients ◽  
2019 ◽  
Vol 11 (1) ◽  
pp. 119 ◽  
Author(s):  
Hugo Monrroy ◽  
Teodora Pribic ◽  
Carmen Galan ◽  
Adoracion Nieto ◽  
Nuria Amigo ◽  
...  

Various conditioning factors influence the sensory response to a meal (inducible factors). We hypothesized that inherent characteristics of the eater (constitutive factors) also play a role. The aim of this proof-of-concept study was to determine the role of gender, as an individual constitutive factor, on the meal-related experience. Randomized parallel trial in 10 women and 10 men, comparing the sensations before, during, and after stepwise ingestion of a comfort meal up to full satiation. Comparisons were performed by repeated Analysis of Covariance (ANCOVA) measures. During stepwise ingestion, satisfaction initially increased up to a peak, and later decreased down to a nadir at the point of full satiation. Interestingly, the amount of food consumed at the well-being peak was lower, and induced significantly less fullness in women than in men. Hence, men required a larger meal load and stronger homeostatic sensations to achieve satisfaction. The same pattern was observed at the level of full satiation: men ate more and still experienced positive well-being, whereas in women, well-being scores dropped below pre-meal level. The effect of gender on the ingestion experience suggests that other constitutive factors of the eater may also influence responses to meals.

Thorax ◽  
2014 ◽  
Vol 69 (Suppl 2) ◽  
pp. A6-A6
Author(s):  
J. Feary ◽  
Z. Lightfoot ◽  
B. FItzgerald ◽  
S. Schofield ◽  
M. Jones ◽  
...  

2020 ◽  
Vol 2020 (4) ◽  
Author(s):  
J Metzemaekers ◽  
P Haazebroek ◽  
M J G H Smeets ◽  
J English ◽  
M D Blikkendaal ◽  
...  

Abstract STUDY QUESTION Is electronic digital classification/staging of endometriosis by the EQUSUM application more accurate in calculating the scores/stages and is it easier to use compared to non-digital classification? SUMMARY ANSWER We developed the first digital visual classification system in endometriosis (EQUSUM). This merges the three currently most frequently used separate endometriosis classification/scoring systems (i.e. revised American Society for Reproductive Medicine (rASRM), Enzian and Endometriosis Fertility Index (EFI)) to allow uniform and adequate classification and registration, which is easy to use. The EQUSUM showed significant improvement in correctly classifying/scoring endometriosis and is more user-friendly compared to non-digital classification. WHAT IS KNOWN ALREADY Endometriosis classification is complex and until better classification systems are developed and validated, ideally all women with endometriosis undergoing surgery should have a correct rASRM score and stage, while women with deep endometriosis (DE) should have an Enzian classification and if there is a fertility wish, the EFI score should be calculated. STUDY DESIGN, SIZE, DURATION A prospective endometriosis classification proof of concept study under experts in deep endometriosis was conducted. A comparison was made between currently used non-digital classification formats for endometriosis versus a newly developed digital classification application (EQUSUM). PARTICIPANTS/MATERIALS, SETTING, METHODS A hypothetical operative endometriosis case was created and summarized in both non-digital and digital form. During European endometriosis expert meetings, 45 DE experts were randomly assigned to the classic group versus the digital group to provide a proper classification of this DE case. Each expert was asked to provide the rASRM score and stage, Enzian and EFI score. Twenty classic forms and 20 digital forms were analysed. Questions about the user-friendliness (system usability scale (SUS) and subjective mental effort questionnaire (SMEQ)) of both systems were collected. MAIN RESULTS AND THE ROLE OF CHANCE The rASRM stage was scored completely correctly by 10% of the experts in the classic group compared to 75% in the EQUSUM group (P < 0. 01). The rASRM numerical score was calculated correctly by none of the experts in the classic group compared with 70% in the EQUSUM group (P < 0.01). The Enzian score was correct in 60% of the classic group compared to 90% in the EQUSUM group (P = 0.03). EFI scores were calculated correctly in 25% of the classic group versus 85% in the EQUSUM group (P < 0.01). Finally, the usability measured with the SUS was significantly better in the EQUSUM group compared to the classic group: 80.8 ± 11.4 and 61.3 ± 20.5 (P < 0.01). Also the mental effort measured with the SMEQ was significant lower in the EQUSUM group compared to the classic group: 52.1 ± 18.7 and 71.0 ± 29.1 (P = 0.04). Future research should further develop and confirm these initial findings by conducting similar studies with larger study groups, to limit the possible role of chance. LIMITATIONS, REASONS FOR CAUTION These first results are promising, however it is important to note that this is a preliminary result of experts in DE and needs further testing in daily practice with different types (complex and easy) of endometriosis cases and less experienced gynaecologists in endometriosis surgery. WIDER IMPLICATIONS OF THE FINDINGS This is the first time that the rASRM, Enzian and EFI are combined in one web-based application to simplify correct and automatic endometriosis classification/scoring and surgical registration through infographics. Collection of standardized data with the EQUSUM could improve endometriosis reporting and increase the uniformity of scientific output. However, this requires a broad implementation. STUDY FUNDING/COMPETING INTEREST(S) To launch the EQUSUM application, a one-time financial support was provided by Medtronic to cover the implementation cost. No competing interests were declared. TRIAL REGISTRATION NUMBER N/A.


2021 ◽  
Author(s):  
Giulia Bassi ◽  
Claudio Giuliano ◽  
Alessio Perinelli ◽  
Stefano Forti ◽  
Silvia Gabrielli ◽  
...  

BACKGROUND Adults with Diabetes Mellitus (DM) present difficulties in maintaining healthy behaviors, in which motivation represents a core component, since it allows them to adhere to clinical recommendations. Virtual Coaches (VCs) have recently become more relevant in supporting and treating common barriers associated with adherence among adults with DM, especially concerning medical and physical aspects. However, few VCs are aimed at supporting adults with DM from a psychosocial perspective. OBJECTIVE This proof-of-concept study aimed to evaluate—at pre-, post-intervention and follow-up—the preliminary efficacy of a VC intervention in motivating adults with DM to reduce depression, anxiety, perceived stress symptoms, diabetes-emotional distress, and improve their well-being, by encouraging them to adopt psychosocial healthy coping strategies. In addition, users’ experience and engagement with a VC were assessed. METHODS A total of 13 Italian adults with DM (18-51 years) were recruited using snowball sampling via social media and a standardized psychosocial tools battery was applied at pre-, post-intervention, and follow-up. Participation in the study implied having access to a VC called Motibot, which stands for Motivational bot, within the Telegram application, based on Natural Language Understanding (NLU). Its intent is to motivate the user to adopt and cultivate healthy coping strategies based on the American Association of Diabetes Educators’ (AADE) guidelines as well as on Mindfulness-Based Cognitive Therapy. Motibot interacts with users in compliance with the Transtheoretical Model of Change, in order to deliver the most appropriate psychoeducational intervention tailored to the user's motivation to change. The interaction covered 12 sessions—each one lasting 10-20 minutes—during which the user could dialogue with the VC by inputting text or tapping an option on their smartphone screen. RESULTS Over the 12 sessions there were no significant changes at pre-, post-intervention, and follow-up concerning the psychosocial factors. However, most users showed a downward trend over the three time periods in depression and anxiety symptoms—except for perceived stress symptoms, which remained moderate for the whole intervention—thereby presenting good psychological well-being and no diabetes-emotional distress. Moreover, users felt motivated, involved, encouraged, emotionally understood, and stimulated by Motibot during the interaction. Indeed, the analyses of interviews through a text mining approach confirmed that Motibot is capable of supporting and motivating adults with DM to adopt healthy coping strategies and reduce anxiety, depression, and perceived stress symptoms. Users also reported having a positive and interesting experience with Motibot, particularly regarding the mindfulness audio tracks and the encouragement for self-reflection on their own emotions. CONCLUSIONS A VC developed using NLU was well-accepted by users, particularly due to the presence of a mindfulness pathway, which motivated them to adopt healthy coping skills. Cultivating healthy coping strategies allows adults to reduce anxiety and depression symptoms as well as diabetes-related emotional distress, and to improve their well-being.


2018 ◽  
Vol 14 (1) ◽  
pp. 45-50 ◽  
Author(s):  
Elena Sticchi ◽  
Betti Giusti ◽  
Antonella Cordisco ◽  
Anna Maria Gori ◽  
Alice Sereni ◽  
...  

2017 ◽  
Vol 19 (10) ◽  
pp. 7307-7315 ◽  
Author(s):  
Yanhui Zhang ◽  
Rongying Dai ◽  
Shirong Hu

A proof-of-concept study follow RGO introduced into TiO2 with oxygen vacancies, the role of oxygen vacancies as active sites in reduced graphene oxide-modified TiO2.


Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Arjune Sen ◽  
Mary Akinola ◽  
Xin You Tai ◽  
Mkael Symmonds ◽  
Gabriel Davis Jones ◽  
...  

Abstract Background Although Alzheimer’s disease affects around 800,000 people in the UK and costs almost £23 billion per year, currently licenced treatments only offer modest benefit at best. Seizures, which are more common in patients with Alzheimer’s disease than age matched controls, may contribute to the loss of nerve cells and abnormal brain discharges can disrupt cognition. This aberrant electrical activity may therefore present potentially important drug targets. The anti-seizure medication levetiracetam can reduce abnormal cortical discharges and reverse memory deficits in a mouse model of Alzheimer’s disease. Levetiracetam has also been shown to improve memory difficulties in patients with mild cognitive impairment, a precursor to Alzheimer’s disease. Clinical use of levetiracetam is well-established in treatment of epilepsy and extensive safety data are available. Levetiracetam thus has the potential to provide safe and efficacious treatment to help with memory difficulties in Alzheimer’s disease. Methods The proposed project is a proof of concept study to test whether levetiracetam can help cognitive function in people with dementia. We plan to recruit thirty patients with mild to moderate Alzheimer’s disease with no history of previous seizures or other significant co-morbidity. Participants will be allocated to a double-blind placebo-controlled crossover trial that tests levetiracetam against placebo. Standardised scales to assess cognition and a computer-based touchscreen test that we have developed to better detect subtle improvements in hippocampal function will be used to measure changes in memory. All participants will have an electroencephalogram (EEG) at baseline. The primary outcome measure is a change in the computer-based touchscreen cognitive task while secondary outcomes include the effect of levetiracetam on mood, quality of life and modelling of the EEG, including time series measures and feature-based analysis to see whether the effect of levetiracetam can be predicted. The effect of levetiracetam and placebo will be compared within a given patient using the paired t-test and the analysis of covariance adjusting for baseline values. Discussion This is the first study to evaluate if an anti-seizure medication can offer meaningful benefit to patients with Alzheimer’s disease. If this study demonstrates at least stabilisation of memory function and/or good tolerability, the next step will be to rapidly progress to a larger study to establish whether levetiracetam may be a useful and cost-effective treatment for patients with Alzheimer’s disease. Trial registration ClinicalTrials.govNCT03489044. Registered on April 5, 2018.


2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e21570-e21570 ◽  
Author(s):  
Stefano Magno ◽  
Stefania Carnevale ◽  
Francesco Dentale ◽  
Daniela Belella ◽  
Marinella Linardos ◽  
...  

e21570 Background: Neo-Adjuvant Chemotherapy (NAC) is commonly recommended as a preoperative treatment for patients with locally advanced breast cancers (BC). However, several studies have shown that NAC can increase patients’ distress. A first aim of this study was to evaluate if BC patients treated with NAC show higher levels of distress as compared to patients undergoing primary surgery (PS). A secondary aim was to evaluate if distress could be significantly correlated with patients’ depression and anxiety, and if generalized self-efficacy (GSE) may moderate these relationships. Methods: one hundred and twenty-four BC patients (61 waiting for PS and 63 undergoing NAC), with a mean age of 51.64 (SD = 9.67), were instructed to complete a series of questionnaires evaluating socio-demographic data, anxiety, depression, distress and GSE. Results: An analysis of covariance was conducted, including treatment condition (NAC vs PS) as an independent variable, patients’ distress as a dependent variable, and age as a covariate. A significant mean difference emerged between groups [F(1, 121) = 5.66, p < .05)]. In particular, NAC patients showed a higher distress (Mean = 6.79) than PS ones (Mean = 5.72). Moreover, patients’ distress appeared moderately correlated with both anxiety (r = .34, p < .05) and depression (r = .36 < .05). Finally, results revealed a significant interaction effect of distress and GSE on depression (β = -.19, p < .05), confirming the moderating role of GSE. In particular, for low levels of GSE (-1 SD), the correlation between distress and depression was large and significant (r = .53, p < .001), while for high level of GSE (+1 SD) this relationship was definitively lower (r = .14, p = .03). No significant moderating effects of GSE were found for stress-anxiety relationship. Conclusions: Results of this study seems to confirm that NAC may induce distress in BC patients. Moreover, distress, significantly related to anxiety and depression, may play a detrimental role for patients’ psychological well-being. Finally, GSE emerged as a moderator of distress-depression relationship, suggesting that negative consequences of stress could be reduced during NAC using GSE-based psychological intervention.


2021 ◽  
Author(s):  
Arjune Sen ◽  
Mary Akinola ◽  
Xin You Tai ◽  
Mkael Symmonds ◽  
Gabriel Davis Jones ◽  
...  

Abstract Background: Although Alzheimer’s disease affects around 800,000 people in the UK and costs almost £23 billion per year, currently licensed treatments only offer modest benefit at best. Seizures, which are more common in patients with Alzheimer’s disease than age matched controls, may contribute to the loss of nerve cells and abnormal brain discharges can disrupt cognition. This aberrant electrical activity may therefore present potentially important drug targets.The anti-epileptic drug levetiracetam can reduce abnormal cortical discharges and reverse memory deficits in a mouse model of Alzheimer’s disease. Levetiracetam has also been shown to improve memory difficulties in patients with mild cognitive impairment, a pre-cursor to Alzheimer’s disease. Clinical use of levetiracetam is well-established in treatment of epilepsy and extensive safety data are available. Levetiracetam thus has the potential to provide safe and efficacious treatment to help with memory difficulties in Alzheimer’s disease.Methods:The proposed project is a proof of concept study to test whether levetiracetam can help cognitive function in people with dementia. We plan to recruit thirty patients with mild to moderate Alzheimer’s disease with no history of previous seizures or other significant co-morbidity. Participants will be allocated to a double-blind placebo controlled crossover trial that tests levetiracetam against placebo. . Standardised scales to assess cognition and a computer-based touch screen test that we have developed to better detect subtle improvements in hippocampal function will be used to measure changes in memory. All participants will have an electroencephalogram (EEG) at baseline. The primary outcome measure is a change in the computer-based touchscreen cognitive task while secondary outcomes include the effect of levetiracetam on mood, quality of life and modelling of the EEG, including time series measures and feature based analysis to see whether effect of levetiracetam can be predicted. The effect of levetiracetam and placebo will be compared within a given patient using the paired t-test and the analysis of covariance adjusting for baseline values Discussion:This is the first study to evaluate if an anti-epileptic medication can offer meaningful benefit to patients with Alzheimer's disease. If this study demonstrates at least stabilisation of memory function and/or good tolerability, the next step will be to rapidly progress to a larger study to establish whether levetiracetam may be a useful and cost-effective treatment for patients with Alzheimer's disease.Trial registration: ClinicalTrials.gov Identifier: NCT03489044Registered: 5th April 2018URL: https://clinicaltrials.gov/ct2/show/NCT03489044


Sign in / Sign up

Export Citation Format

Share Document